ANNEE 2020

Publié le 25/02/2021 à 09h19 (mis à jour le 25/10/2022 à 12h13)


Barthez S, Revet A, Chouchana L, Jonville-Bera AP, Pizzoglio V, Raynaud JP, Chebane L, Lapeyre-Mestre M, Montastruc F. Adverse drug reactions in infants, children and adolescents exposed to antidepressants : a French pharmacovigilance study. Eur J Clin Pharmacol. 2020 ;76:1591-1599.

Bertrand V, Massy N, Pigneur B, Coopman S, Durrieu G, Gaboriau L, Langlois V, Gower-Rousseau C, Hugot JP, Ruemmele FM ; GETAID (Groupe d’Etude thérapeutique des Affections Inflammatoires du Tube Digestif) Pediatrique1. Neurological Adverse Effects Associated With Anti-tumor Necrosis Factor Alpha Antibodies in Pediatric Inflammatory Bowel Diseases. J Pediatr Gastroenterol Nutr. 2020 ;70:841-848.

Bordet C, Rousseau V, Montastruc F, Montastruc JL. QT prolongation and vortioxetine : a post-marketing study and comparison with other serotonin reuptake inhibitors. Psychopharmcology. 2020 ;237:1245-1247.

Baudou E, Lespine A, Durrieu G, André F, Gandia P, Durand C, Cunat S. Serious Ivermectin Toxicity and Human ABCB1 Nonsense Mutations. N Engl J Med. 2020 ;383:787-789.

Bourrel C, Zacarin A, Rousseau V, Montastruc JL, Bagheri H. Are potentially inappropriate and anticholinergic medications being prescribed for institutionalized elderly subjects ? Fundam Clin Pharmacol. 2020 ;34:743-748.

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Yu et al. "Levothyrox® New and Old Formulations : Are They Switchable for Millions of Patients ?". Clin Pharmacokinet. 2020 ;59:283-285.

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Krebs-Brown et al. Comment on : "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One ?". Clin Pharmacokinet. 2020 ;59:269-271.

Concordet D, Gandia P, Montastruc JL, Bousquet‑Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Nicolas : Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One ? Clin Pharmacokinet. 2020 ;59:277-279.

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL. Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One ? Clin Pharmacokinet. 2020 ;59:1-5.

Conte C, Rousseau V, Vert C, Montastruc F, Montastruc JL, Durrieu G, Olivier P. Adverse drug reactions of statins in children and adolescents : a descriptive analysis from VigiBase, the WHO global database of individual case safety reports. Fundam Clin Pharmacol. 2020 ;34:518-520.

Cottin J, Pierre S, Pizzoglio V, Simon C, Durrieu G, Bleyzac N, Gouraud A, Dumortier J. Methylprednisolone-related liver injury : A descriptive study using the French pharmacovigilance database. Clin Res Hepatol Gastroenterol. 2020 ;44:662-673.

de Germay S, Bagheri H, Despas F, Rousseau V, Montastruc F. Abatacept in rheumatoid arthritis and the risk of cancer : a world observational post-marketing study. Rheumatology (Oxford). 2020 ;59:2360-2367.

de Germay S, Montastruc F, Carvajal A, Lapeyre-Mestre M, Montastruc JL. Drug-induced parkinsonism : Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism Relat Disord. 2020 ;70:55-59.

Foubert-Samier A, Pavy-Le Traon A, Guillet F, Le-Goff M, Helmer C, Tison F, Rascol O, Proust-Lima C, Meissner WG. Disease progression and prognostic factors in multiple system atrophy : A prospective cohort study. Neurobiol Dis. 2020 ;139:104813.

Fouque C, Martin R, Seguro F, Montastruc JL, de Canecaude C. Splenic Infarction in a Narcoleptic Patient Treated With Methylphenidate, Venlafaxine, and Pitolisant. Ann Pharmacother. 2020 ;54:189-190.

Garcia P, Revet A, Yrondi A, Rousseau V, Degboe Y, Montastruc F. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID‑19) : A VigiBase Study. Drug Saf. 2020 ;43:1315-1322.

Hakimi Y, Petitpain N, Pinzani V, Montastruc JL, Bagheri H. Paradoxical adverse drug reactions : descriptive analysis of French reports. Eur J Clin Pharmacol. 2020 ;76:1169-1174.

Hillaire-Buy D, Mousset, Allouchery M, Azzouz B, Babin M, Bellet F, Béné B, Default A, Durrieu G, Géniaux H, Grandvuillemin A, Gras-Champel V, Jantzem H, Lambert A, Lepelley M, Massy N, Petitpain N, Rocher F, sanchez-Pena P, Sassier M, Simon C, Triquet L, Valnet-Rabier MB, Veyrac G, Faillie JL, Zenut MC. Liquid formulation of ifosfamide increased risk of encephalopathy : A case-control study in a pediatric population. Therapies. 2020 ;75:471-780.

Jacquot J, Rousseau V, de Canecaude C, Montastruc JL, Durrieu G. Interest of a general practitioner pharmacovigilance network to provide drug information : A comparative study in Franc. Therapies. 2020 ;75:617-622.

Lafaurie M, Olivier P, Khouri C, Atzenhoffer M, Bihan K, Durrieu G, Montastruc JL. Myocardial infarction and ischemic stroke with vasoconstrictors used as nasal decongestant for common cold : a French pharmacovigilance survey. Eur J Clin Pharmacol. 2020 ;76:603-604.

Lemaitre F, Solas C, Grégoire M, Lagarce L, Elens L, Polard E, Saint-Salvi B, Sommet A, Tod M, Barin-Le Guellec C. Potential drug–drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. Fundam Clin Pharmacol. 2020 ;34:530-547.

Maquet J, Lafaurie M, Sommet A, Moulis G. Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19. Br J Haematol. 2020 ;190:e276-e279.

Maquet J, Derumeaux H, Lapeyre-Mestre M, Sailler L, Moulis G. Validation of hemolytic anemia discharge diagnosis codes in the French hospital database. Eur J Intern Med. 2020 ;79:136-138.

Montastruc F, Thuriot S, Durrieu G. Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019. Clin Gastroenterol Hepatol. 2020 ;18:2835-2836.

Montastruc JL, Rousseau V, de Canecaude C, Roussin A, Montastruc F. Role of serotonin and norepinephrine transporters in antidepressant-induced arterial hypertension : a pharmacoepidemiological-pharmacodynamic study. Eur J Clin Pharmacol. 2020 ;76:1321-1327.

Montastruc JL, Toutain PL. A New Drug–Drug Interaction Between Hydroxychloroquine and Metformin ? A Signal Detection Study. Drug Saf. 2020 ;43:657-660.

Montastruc JL, Rousseau V, Durrieu G, Bagheri H. Serious adverse drug reactions with hydroxychloroquine : a pharmacovigilance study in Vigibase®. Eur J Clin Pharmacol. 2020 ;76:1479-1480.

Pacheco-Paez T, Montastruc F, Rousseau V, Chebane L, Lapeyre-Mestre M, Renoux C, Montastruc JL. Parkinsonism associated with gabapentinoid drugs : A pharmacoepidemiologic study. Mov Disord. 2020 ;35:176-180.

Pacheco-Paez T, Montastruc F, Rousseau V, Chebane L, Lapeyre-Mestre M, Renoux C, Montastruc JL. Reply to : Comment on "Parkinsonism associated with gabapentinoid drugs : A pharmacoepidemiological study". Mov Disord. 2020 ;35:376-377.

Pradhan R, Montastruc F, Rousseau V, Patorno E, Azoulay L. Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions : a pharmacovigilance analysis. Lancet Diabetes Endocrinol. 2020 ;8:13-14.

Strumia M, Felipe Guerrero F, Maurel-Ribes A, Garcia E, Payrastre B, Haleh Bagheri H. Platelet function defects and sertraline-induced bleeding : a case report. Fundam Clin Pharmacol. 2020 ;34:632-636.

Vacher R, Lagarce L, Ghamrawi S, Laugier‐Castellan D, Vial T, Bagheri H, Babin M, Briet M. Drug interactions related to self‐medication : a French pharmacovigilance database study. Fundam Clin Pharmacol. 2020 ;34:623-631.

Watson S, Durrieu G. Midostaurin, photosensitivity reaction. WHO Pharm. 2020 ;2:19.

Zacarin A, Strumia M, Piau A, Bagheri H. Potentially inappropriate medication : Adaptation of EU(7)PIM criteria to the French medical practice. Therapies. 2020 ;75:663-673.

Zelmat Y, Rousseau V, Chebane L, Montastruc JL, Bagheri H, Sommet A. Fluoroquinolone-Induced Photosensitivity : A Chemical Fragment-Based Approach by a Case/Non-case Study in VigiBase®. Drug Saf. 2020 ;43:561-566.


Dupouy J, Maumus-Robert S, Mansiaux Y, Pariente A, Lapeyre-Mestre M. Primary Care of Opioid use Disorder : The End of “the French Model” ? Eur Addict Res. 2020 ;26:346-354.

Gentile G, Lapeyre-Mestre M, Micallef J. Combatting the misuse of benzodiazepines and related Z drugs in French general practice : a clinical review. BJGP Open. 2020 ;4:1-7.

Jouanjus E, Wolff V. Cannabis et atteintes vasculaires cérébrales. État des connaissances sur les pathologies cérébrovasculaires observées dans un contexte d’usage de cannabis. Presse Med Form. 2020 ;1:364-372.

Lapeyre-Mestre M. Novel forms of injectable buprenorphine and French model of opioid use disorder treatment. Therapies. 2020 ;75:393-395.

Lapeyre-Mestre M, Jouanjus E. Cannabis et pathologies cardio-vasculaires. Synthèse des données récentes sur les caractéristiques des complications cardiovasculaires dues aux cannabinoïdes. Presse Med Form. 2020 ;1:355-363.

Lapeyre-Mestre M. The challenges of pharmacoepidemiology of orphan drugs in rare diseases. Therapies. 2020 ;75:215-220.

Lapeyre-Mestre M, Boucher A, Daveluy A, Gibaja V, Jouanjus E, Mallaret M, Peyrière H, Micallef J. Addictovigilance contribution during COVID-19 epidemic and lockdown in France. Therapie. 2020 ;75:343-354.

Mongiatti M, Bayle P, Lagarrigue A, Fabre D, Telmon N, Lapeyre-Mestre M, Jouanjus E. The cardiovascular health of prisoners who use cannabis : An exploratory study among hospitalized prisoners. Therapies. 2020 ;75:579-589.


Bagheri H. Characteristics of self-medication in French students. Therapies. 2020 ;75:417-418

Bénard-Laribière A, Pambrun E, Sutter-Dallay AL, Gautier S, Hurault-Delarue C, Damase-Michel C, Lacroix I, Pariente A. Impact of pregnancy on antidepressant treatment course : a population-based comparative cohort study in France. Arch Womens Ment Health. 2020 ;23:699-707.

Conte C, Lapeyre-Mestre M, Hanaire H, Ritz P. Diabetes Remission and Relapse After Bariatric Surgery : a Nationwide Population-Based Study. Obes Surg. 2020 ;30:4810-4820.

Couret A, Gallini A, Poncet M, Renoux A, Maryse Lapeyre-Mestre M, Gardette V. Benzodiazepine Dispensing to Persons With Dementia in France 2011-2016 : A Nationwide Study. JAMDA. 2020 ;21:830-836.

De Almeida Chaves S, Derumeaux H, Do Minh P, Lapeyre-Mestre M, Moulis G, Pugnet G. Assessment of the Accuracy of Using ICD-10 Codes to Identify Systemic Sclerosis. Clin Epidemiol. 2020 ; 12 : 1355–1359.

de Germay S, Conte C, Rascol O, Montastruc JL, Lapeyre-Mestre M.  β-Adrenoceptor Drugs and Parkinson’s Disease : A Nationwide Nested Case-Control Study. CNS Drugs. 2020 ;34:763-772.

Dumas PY, Bertoli S, Bérard E, Leguay T, Tavitian S, Galtier J, Alric C, Bidet A, Delabesse E, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, Rey H, de Grande AC, Despas F, Pigneux A, Récher C. Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome. Blood Adv. 2020 ;4:3840-3849.

Gauthier M, Conte C, Palmaro A, Patras De Campaigno E, De Barros S, Huguet F, Laurent G, Lapeyre-Mestre M, Despas F. Psychotropic drug initiation in patients diagnosed with chronic myeloid leukemia : a population-based study in France. Fundam Clin Pharmacol. 2020 ;34:612-622.

Ihle J, Artaud F, Bekadar S, Mangone G, Sambin S, Mariani LL, Bertrand H, Rascol O, Durif F, Derkinderen P, Scherzer C, Elbaz A, Corvol JC ; DIGPD study group ; Steering committee, Corvol JC, Elbaz A, Vidailhet M, Brice A ; Statistical analyses, Elbaz A, Artaud F ; Principal investigators for sites, Bourdain F, Brandel JP, Corvol JC, Derkinderen P, Durif F, Levy R, Pico F, Rascol O ; Co-investigators (alphabetical order), Bonnet AM, Bonnet C, Brefel-Courbon C, Cormier-Dequaire F, Degos B, Debilly B, Elbaz A, Galitsky M, Grabli D, Hartmann A, Klebe S, Kraemmer J, Lacomblez L, Leder S, Mangone G, Mariani LL, Marques AR, Mesnage V, Muellner J, Ory-Magne F, Planté-Bordeneuve V, Roze E, Tir M, Vidailhet M, You H ; Neuropsychologists, Benchetrit E, Socha J, Pineau F, Vidal T, Pomies E, Bayet V ; Genetic core, Brice A, Lesage S, Tahiri K, Bertrand H, Mangone G ; Sponsor activities and clinical research assistants, Mallet A, Villeret C, Mazmanian M, Manseur H, Hajji M, Le Toullec B, Brochard V, Roy M, Rieu I, Bernard S, Faurie-Grepon A. Parkinson’s disease polygenic risk score is not associated with impulse control disorders : A longitudinal study. Parkinsonism Relat Disord. 2020 ;75:30-33.

Jourdes A, Lafaurie M, Martin-Blondel G, Delobel P, Faruch M, Charpentier S, Minville V, Silva S, Thalamas C, Sommet A, Moulis G. Clinical characteristics and outcome of hospitalized patients withSARS-CoV-2 infection at Toulouse University hospital (France).Results from the Covid-clinic-Toul cohort. Rev Med Int. 2020 ;41:732-740.

Lacroix I, Bénévent J, Damase-Michel C. Chloroquine and hydroxychloroquine during pregnancy : What do we know ? Therapies. 2020 ;384-385.

Lafaurie M, Baricault B, Soler V, Cassagne M, Sailler L, Lapeyre-Mestre M, Sommet A, Moulis G. No increased risk of cataract in adult patients with primary immune thrombocytopenia treated with eltrombopag. A French nationwide nested case-control study. B J Haemat. 2020 ;189:e137-e140.

Lastennet D, Mariani LL, Rascol O, Turc JD, Alfaisal H, Lapeyre-Mestre M, Corvol JC, Tubach F. Evaluation of Prescription Practices of Domperidone in Parkinson’s Disease : A Cross Sectional Study Among French Neurologists. CNS Drugs. 2020 ;34:1267-1274.

Maquet J, Lafaurie M, Sommet A, Moulis G. Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19. Br J Haematol. 2020 ;190:e276-e279.

Montastruc F, Romano C, Montastruc JL, Silva S, Seguin T, Minville V, Georges B, Riu-Poulenc B, Fourcade O. Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to Intensive Care Unit in South of France. Therapies. 2020 ;75:381-388.

Moulis G, Comont T, Germain J, Sommet A, Lapeyre-Mestre M, Beyne-Rauzy O, Adoue D ; CARMEN investigators group. Significance of antinuclear antibodies in primary immune thrombocytopenia : results of the CARMEN registry. Blood Adv. 2020 ;4:1974-1977.

Mounié M, Costa N, Conte C, Petiot D, Fabre D, Despas F, Lapeyre-Mestre M, Laurent G, Savy N, Molinier L. Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France. J Med Econ. 2020 ;23:235-242.

Piel-Julian ML, Thiercelin-Legrand MF, Moulis G, Voisin S, Claeyssens S, Sailler L. Antithrombotic therapy management in patients with inherited bleeding disorders and coronary artery disease : A single-centre experience. Haemophilia. 2020 ;26:e34-e37.

Poncet M, Gardette V, Couret A, Renoux A, Lapeyre-Mestre M, Gallini A. Benzodiazepine exposure in subjects with incident Alzheimer’s disease and related syndromes in France : a longitudinal study 2011-2017. Int Clin Psychopharmacol. 2020 ;35:270-278.

Pugnet G, Mounié M, Lapeyre-Mestre M, Moulis G, Sailler L. Insufficient influenza vaccination coverage in giant cell arteritis. A French population-based study. Rev Med Interne. 2020 ;41:446-450.

Rascol O, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Fabbri M, Meissner WG, Rachdi A, Tison F, Perez-Lloret S ; COPARK Study Group. Excessive buccal saliva in patients with Parkinson’s disease of the French COPARK cohort. J Neural Transm. 2020 ;127:1607-1617.

Rascol O, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Fabbri M, Meissner WG, Rachdi A, Tison F, Perez-Lloret S ; COPARK Study Group. Utilization Patterns of Amantadine in Parkinson’s Disease Patients Enrolled in the French COPARK Study. Drugs Aging. 2020 ;37:215-223.

Rousset S, Treiner E, Moulis G, Pugnet G, Astudillo L, Paricaud K, Puissant-Lubrano B, Arlet P, Blancher A, Sailler L. High rate of indeterminate results of the QuantiFERON-TB Gold in-tube test, third generation, in patients with systemic vasculitis. Rheumatology (Oxford). 2020 ;59:1006-1010.

Roustit R, Guilhaumou R, Molimard M, Drici MD, laporte S, Montastruc JL. On behalf of the French Society of Pharmacology and Therapeutics (SFPT). Chloroquine and hydroxychloroquine in the management of COVID-19 : Much kerfuffle but little evidence. Therapies. 2020 ;75:363-370.

Souty C, Launay T, Steichen O, Conte C, Turbelin C, Sarazin M, Vilcu AM, Rossignol L, Blanchon T, Lapeyre-Mestre M, Hanslik T. Use of the French healthcare insurance database to estimate the prevalence of exposure to potential drug-drug interactions. Eur J Clin Pharmacol. 2020 ;76:1675-1682.

Vayr F, Montastruc M, Savall F, Despas F, Judic E, Basso M, Dunet C, Dalenc F, Laurent G, Soulat JM, Herin F. Work adjustments and employment among breast cancer survivors : a French prospective study. Support Care Cancer. 2020 ;28:185-192.

Zacarin A, Pradalié P, Bourgade B, Bayle H, Mestery D, Bagheri H. Evolution of drug prescription pattern in elderly : Retrolective study in a general hospital center in France. Therapies. 2020 ;75:271-279.


Barbe MT, Tonder L, Krack P, Debû B, Schüpbach M, Paschen S, Dembek TA, Kühn AA, Fraix V, Brefel-Courbon C, Wojtecki L, Maltête D, Damier P, Sixel-Döring F, Weiss D, Pinsker M, Witjas T, Thobois S, Schade-Brittinger C, Rau J, Houeto JL, Hartmann A, Timmermann L, Schnitzler A, Stoker V, Vidailhet M, Deuschl G ; EARLYSTIM study group. Deep Brain Stimulation for Freezing of Gait in Parkinson’s Disease With Early Motor Complications. Mov Disord. 2020 ;35:82-90.

Blin O, Lefebvre MN, Rascol O, Micallef J. Orphan drug clinical development. Therapies. 2020 ;75:141-147.

Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Ory-Magne F, Rascol O, Moreau C, Maltête D, Rouaud T, Meyer M, Houvenaghel JF, Marsé C, Tranchant C, Hainque E, Jarraya B, Ansquer S, Bonnet M, Belamri L, Tir M, Marques AR, Danaila T, Eusebio A, Devos D, Brefel-Courbon C ; PREDI-STIM study group*. Personality Dimensions Are Associated with Quality of Life in Fluctuating Parkinson’s Disease Patients (PSYCHO-STIM). J Parkinsons Dis. 2020 ;10:1057-1066.

Brosseron F, Kolbe CC, Santarelli F, Carvalho S, Antonell A, Castro-Gomez S, Tacik P, Namasivayam AA, Mangone G, Schneider R, Latz E, Wüllner U, Svenningsson P, Sánchez-Valle R, Molinuevo JL, Corvol JC, Heneka MT, Rascol O ; AETIONOMY study group. Multicenter Alzheimer’s and Parkinson’s disease immune biomarker verification study. Alzheimers Dement. 2020 ;16:292-304.

Crepin S, Chiffoleau A, Gavard M, Olivier-Abbal P, Roussillon C, Ruault S, Muller C, Peyro-Saint-Paul L, Ouk T, Franceschi MP, Mouchel C, Duranton S, Petitpain N, Coubret-Dumas A. Compliance of French academic clinical trials with the Clinical Trial Facilitation and Coordination Group recommendations on contraception and pregnancy testing requirements. Clin Trials. 2020 ;17:314-322.

Del Campo N, Phillips O, Ory-Magne F, Brefel-Courbon C, Galitzky M, Thalamas C, Narr KL, Joshi S, Singh MK, Péran P, Pavy-LeTraon A, Rascol O. Broad white matter impairment in multiple system atrophy. Hum Brain Mapp. 2020 ;42:357-66.

Fabbri M, Kauppila LA, Ferreira JJ, Rascol O. Challenges and Perspectives in the Management of Late-Stage Parkinson’s Disease. J Parkinsons Dis. 2020 ;10:S75-S83.

Fabbri M, Perez-Lloret S, Rascol O. Therapeutic strategies for Parkinson’s disease : promising agents in early clinical development. Expert Opin Investig Drugs. 2020 ;29:1249-1267.

Gallais F, Ysebaert L, Despas F, De Barros S, Dupré L, Quillet-Mary A, Protin C, Thomas F, Obéric L, Allal B, Chatelut E, White-Koning M. Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. Clin Pharmacokinet. 2020 ;59:1171-1183.

Grosset DG, Dhall R, Gurevich T, Kassubek J, Poewe WH, Rascol O, Rudzinska M, Cormier J, Sedkov A, Oh C. Inhaled levodopa in Parkinson’s disease patients with OFF periods : A randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2020 ;71:4-10.

Kermorgant M, Nasr N, Czosnyka M, Arvanitis DN, Hélissen O, Senard JM, Pavy-Le Traon A. Impacts of Microgravity Analogs to Spaceflight on Cerebral Autoregulation. Front Physiol. 2021 Jul 3 ;11:778.

Kermorgant M, Ben Salem J, Iacovoni JS, Calise D, Dahan L, Guiard BP, Lopez S, Lairez O, Lasbories A, Nasr N, Pavy Le-Traon A, Beaudry F, Senard JM, Arvanitis DN Cardiac sensory afferents modulate susceptibility to anxio-depressive behaviour in a mouse model of chronic heart failure. Acta Physiol (Oxf). 2021 Apr ;231(4):e13601.

Leal Rato M, Rascol O, Ferreira JJ. The "long and winding road" of the disease-modifying effects of levodopa has not ended yet. Mov Disord. 2020 ;35:397-399.

LeWitt PA, Aradi SD, Hauser RA, Rascol O. The challenge of developing adenosine A2A antagonists for Parkinson disease : Istradefylline, preladenant, and tozadenant. Parkinsonism Relat Disord. 2020 ;80:S54-S63.

Markaki I, Bergström S, Tsitsi P, Remnestål J, Månberg A, Hertz E, Paslawski W, Sorjonen K, Uhlén M, Mangone G, Carvalho S, Rascol O, Meissner WG, Magnin E, Wüllner U, Corvol JC, Nilsson P, Svenningsson P. Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson’s Disease. Mov Disord. 2020 ;35:2101-2106.

Meissner WG, Traon AP, Foubert-Samier A, Galabova G, Galitzky M, Kutzelnigg A, Laurens B, Lührs P, Medori R, Péran P, Sabatini U, Vergnet S, Volc D, Poewe W, Schneeberger A, Staffler G, Rascol O ; AFF009 Study Investigators. A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy. Mov Disord. 2020 ;35:1957-1965.

Meyrignac O, Bal L, Zadro C, Vavasseur A, Sewonu A, Gaudry M, Saint-Lebes B, De Masi M, Revel-Mouroz P, Sommet A, Darcourt J, Negre-Salvayre A, Jacquier A, Bartoli JM, Piquet P, Rousseau H, Moreno R. Combining Volumetric and Wall Shear Stress Analysis from CT to Assess Risk of Abdominal Aortic Aneurysm Progression.Radiology. 2020 ;295:722-729.

Pellecchia MT, Stankovic I, Fanciulli A, Krismer F, Meissner WG, Palma JA, Panicker J, Seppi K, Wenning GK, Antonini A, Bajaj S, Bang J, Barone P, Berardelli A, Berg D, Biaggioni I, Bloem B, Brooks DJ, Calandra‐Buonaura G, Colosimo C, Cortelli P, Ferreira J, Fox S, Frauscher B, Freeman R, Fung V, Gasser T, Gerhard A, D. Goldstein, Hallett M, Halliday G, Höglinger GU, Holton JL, Houlden H, Iodice V, Kaufmann H, Klockgether T, Kostic V, Lang A, Ling H, Low P, Litvan I, Miki Y, Nomura T, Orimo S, Ozawa T, Pantelyat A, Postuma R, Quinn N, Rascol O, Robertson D, Sabanovic M, Sakakibara R, Sampaio C, Schmahmann JD, Scholz S, Senard JM, Weintrau D, Siebert U, Poewe W. Can autonomic testing and imaging contribute to the early diagnosis of MSA ? A systematic review and recommendations by the MDS multiple system atrophy (MoDiMSA) study group. Mov Disord Clin Pract. 2020 ;7:750-762.

Phillipps C, Longato N, Béreau M, Carrière N, Lagha-Boukbiza O, Mengin AC, Monga B, Defebvre L, Ory-Magne F, Castrioto A, Lhommée E, Rascol O, Krack P, Tranchant C, Corvol JC, Anheim M. Is Motor Side Onset of Parkinson’s Disease a Risk Factor for Developing Impulsive-Compulsive Behavior ? A Cross-Sectional Study. Mov Disord. 2020 ;35:1080-1081.

Olivot JM, Albucher JF, Guenego A, Thalamas C, Mlynash M, Rousseau V, Drif A, Christensen S, Sommet A, Viguier A, Darcourt J, Calvière L, Menegon P, Raposo N, Januel AC, Bonneville F, Tourdias T, Mazighi M, Sibon I, Albers GW, Cognard C ; FRAME Investigators*. Mismatch Profile Influences Outcome After Mechanical Thrombectomy. Stroke. 2021 ;52:232-240.

Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease : challenges of clinical trials. Nat Rev Neurol. 2020 ;16:97-107.


Bagheri H. Analyse de livre. Automédication, le Guide Expert, J.-P. Giroud. Éditions De La Martinière, Paris (2017). 2020 ;75:125-126.

Montastruc JL. Analyse de livre. Le sport dans la douleur : de l’automédication au mental training, T. Bujon, F. Mougeot, in : Collections sports, cultures, sociétés, Presses universitaires de Grenoble, 38600, Fontaine, France (2017), 108 pp, ISBN : 9782706127038. Therapies. 2020 ;45:126.

Montastruc JL. Analyse de livre. Neuropsychopharmacologie, R. Bordet, L. Carton, J. Deguil, T. Dondaine, sous l’égide de la Société française de pharmacologie et de thérapeutique (SFPT) et du Collège national de pharmacologie médicale (CNPM), Elsevier Masson (2019), EISBN : 9782294754241, 277 pp., ISBN : 9782294752995. Therapies. 2020 ;75:126-127.